Effects of EM1, a vitamin D analogue, on glioblastoma multiforme cells

FERMENTO, M.E.; QUEVEDO, M.A.; VITALE, C.; ALONSO, E.N.; GANDINI, N.A.; MASCARÓ, E.; CURINO, A.C.; FERRONATO, M.J.; OBIOL, D.J.; LÓPEZ ROMERO, A.; FACCHINETTI, M.M.

Buenos Aires

Congreso; LXI Reunión de la Sociedad Argentina de Investigación Clínica (SAIC); 2016

Currently first-line adjuvant treatment of glioblastoma is based on the association of radiotherapy and temozolomide, an oral alkylating agent. Despite the combination treatment has improved patient survival compared to radiotherapy alone, novel strategies that prolog the survival and ensure a better quality of life are necessary. EM1 is a calcitriol analogue that exhibits anti-metastatic effects in a breast cancer animal model without causing hypercalcemia. Also, EM1 is a derivative of a secosteroid therefore it presents a potential to cross the blood-brain barrier. The aim of the present study was to evaluate the potential of EM1 as a chemosensitizing agent in glioblastoma treatment, investigating its antitumoral effects on human T98G and U251 cell lines, and modeling EM1 binding to its receptor VDR by in silico assays. The results showed that the analogue exerted a significant decrease in the viability of the T98G cells through arrest in G0/G1 phase when cell cycle was analized by flow cytometry (p